Krista F. Huybrechts, MS, PhD
Brigham & Women’s Hospital
Department of Medicine
Division of Pharmacoepidemiology & Pharmacoeconomics
1620 Tremont Street, Suite 3030,
Boston, MA 02120
Phone: 617-278-0930 | Fax: 617-232-8602
Krista F. Huybrechts, M.S., Ph.D. is an Instructor in Medicine at Harvard Medical School and an epidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital. Her current research centers on studying the utilization and outcomes of psychoactive medications, with particular reference to vulnerable populations such as the frail elderly and pregnant women. She also has a special interest in exploring how variation in medication prescribing at the level of the physician or institution can be used to improve confounding control in observational studies in the area of psychiatry, as well as the potential impact of regional practice variation on study validity.
Dr. Huybrechts graduated magna cum laude with a Master of Science degree in Economics from the University of Antwerp, Belgium where she also worked as a researcher in health economics. Prior to completing a doctoral degree in epidemiology at Boston University School of Public Health, Dr. Huybrechts held several positions in pharmacoeconomics and outcomes research, both in Europe and the US. Her research projects focused primarily on psychiatry and neurology, and covered a broad spectrum of research designs, including clinical trials, naturalistic studies, retrospective data analyses, and cost-of-illness and decision-analytic simulation models.
Selected Publications | Current PubMed Search Results
Drug Safety and Utilization
- Huybrechts KF, Seeger JD, Rothman KJ, Glynn RJ, Avorn J, Schneeweiss S. Bias in comparative effectiveness studies due to regional variation in medical practice intensity: a legitimate concern, or much ado about nothing? Circ Cardiovasc Qual Outcomes 2012;5(5):e61-4.
- Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential Risk of Death in Older Nursing Home Residents Prescribed Specific Antipsychotic Medications: Population-based Cohort Study. The British Medical Journal 2012 Feb 23;344:e977.
- Huybrechts KF, Schneeweiss S, Gerhard T, Olfson M, Avorn J, Levin R, Lucas JA, Crystal S. Comparative Safety of Antipsychotic Medications in Nursing Home Residents. Journal of the American Geriatric Society 2012;60(3):420-9.
- Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, Schneeweiss S. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharm 2012;32(1):11-7.
- Myers JA, Rassen JA, Gagne JJ, HuybrechtsKF, SchneeweissS, Rothman KJ, Joffe MM, Glynn RJ. Effects of adjusting for instrumental variables on bias and precision of effect estimates. Am J Epidemiol. 2011; 174(11):1213-22.
- Huybrechts KF, Brookhart MA, Rothman KJ, Silliman RA, Gerhard T, Crystal S, Schneeweiss S. Comparison of different approaches to confounding adjustment in a study on the effect of antipsychotic medication on mortality in older nursing home patients. Am J Epidemiol. 2011;174(9):1089-99.
- Cosgrove L, Shi L, Creasey DE, Anaya-McKivergan M, Myers JA, Huybrechts KF. Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers’ financial associations with industry. PLoS One. 2011 Apr 6;6(4):e18210.
- Wise LA, Mikkelsen EM, Rothman KJ, Riis AH, Sørensen HT, Huybrechts KF, Hatch EE. A prospective cohort study of menstrual characteristics and time to pregnancy. Am J Epidemiol. 2011;174(6):701-9.
- Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospitalization for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 2011; 183(7):E411-9.
- Huybrechts KF, Mikkelsen EM, Christensen T, Riis AH, Hatch EE, Wise LA, Sørensen HT, Rothman KJ. A successful implementation of e-epidemiology: the Danish pregnancy planning study ‘Snart-Gravid’. Eur J Epidemiol. 2010; 25(5): 297-304.
- Huybrechts KF, Ishak KJ, Caro JJ. Assessment of Compliance with Osteoporosis Treatment and its Consequences in a Managed Care Population. Bone 2006;38(6):922-928.
- Huybrechts KF, Caro JJ, Xenakis JJ, Vemmos KN. The prognostic value of the modified Rankin Scale score for long-term survival after first-ever stroke. Results from the Athens Stroke Registry. Cerebrovasc Dis 2008;26(4):381-7.
- Caro JJ, Xenakis JG, Huybrechts KF. Ignoring study design heterogeneity in meta-analyses [letter]. Arch Intern Med 2006;166:2046.
- Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis International 2004; 15(12):1003-1008.
- Caro JJ, Huybrechts KF. Case-Control Studies in Pharmacoeconomic Research: An Overview. PharmacoEconomics 2009; 27(8):627-634.
- Huybrechts KF, Caro JJ, Wilson DA, O’Brien JA. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value in Health 2005; 8(5): 549-561.
- Huybrechts KF, Caro JJ, London GM. Modeling the implications of changes in vascular calcification in patients on hemodialysis. Kidney International 2005; 67:1532-1538.
- Caro JJ, Huybrechts KF, Klittich WS, Jackson JJ, McGuire A, for the CORE Study Group. Allocating funds to prevention of cardiovascular disease in light of the NCEP ATPIII guidelines. American Journal of Managed Care 2003; 9(7):477-489.
- Payne KA, Huybrechts KF, Caro JJ, Craig Green TJ, Klittich WS. Long term cost-of-illness in stroke. An international Review. PharmacoEconomics 2002;20(12): 813-25.
- Caro JJ, Huybrechts KF, Kelley H, for the Stroke Economic Analysis Group. Predicting treatment costs after acute ischemic stroke on the basis of patient characteristics at presentation and early dysfunction. Stroke 2001;32(1):100-106.
- Caro JJ, Huybrechts KF, Duchesne I. Management patterns and costs of acute ischemic stroke. An international study. Stroke 2000;31:582-90.
- Caro JJ, Huybrechts KF, for the Stroke Economic Analysis Group. Stroke treatment economic model (STEM): Predicting long-term costs from functional status. Stroke 1999;30:2574-2579.